Key result
Icosapent ethyl outperforms other omega-3s in reducing CVD risk and stabilizing coronary plaque.
Why the study?
Despite reducing LDL cholesterol, residual cardiovascular risk remains, and the role and mechanism of omega-3 fatty acids like EPA on cardiovascular outcomes and coronary plaque warrant evaluation.
Does eicosapentaenoic acid (icosapent ethyl) reduce cardiovascular disease risk and coronary plaque burden in patients on statin therapy?
Does eicosapentaenoic acid (icosapent ethyl) reduce cardiovascular disease risk and coronary plaque burden in patients on statin therapy?
Icosapent ethyl provides cardiovascular benefits and plaque stabilization beyond statin therapy, outperforming other omega-3 fatty acid formulations.
Answers are grounded in this paper and cite their sources.
Supports icosapent ethyl for risk reduction and plaque stabilization on statins; leaves open head-to-head trials versus other omega-3 formulations.
Treatment of established risk factors, especially low-density lipoprotein (LDL) cholesterol, is the cornerstone of preventing atherosclerotic coronary artery disease. Despite reducing LDL cholesterol, there remains a significant risk of cardiovascular disease. Inflammatory and metabolic pathways contribute to recurrence of cardiovascular events, and are often missed in clinical practice. Eicosapentaenoic acid (EPA) may play a crucial role in reducing residual risk of cardiovascular disease. In this review we discuss the clinical applications of omega-3 fatty acids (OM3FAs), their mechanism of action, the difference between pure EPA and docosahexaenoic acid components, and the latest cardiovascular outcome trials and imaging trials evaluating coronary plaque. PubMed and EMBASE were searched to include all the remarkable clinical trials investigating OM3FAs and cardiovascular disease. Beyond statins, additional medications are required to reduce the risk of cardiovascular disease. EPA has shown cardiovascular benefit in addition to statins in large outcome trials. Additionally, multiple serial-imaging studies have demonstrated benefits on plaque progression and stabilization. Due to its pleotropic properties, icosapent ethyl outperforms other OM3FAs in decreasing cardiovascular disease risk in both patients with and without high triglycerides, and is currently recommended as an adjunct to statins. To further strengthen the current evidence, additional research is required to elucidate the inconsistencies between the effects of pure EPA and EPA plus docosahexaenoic acid.
No takes yet. Share an insight, caveat, or question.
Manubolu et al. (2022) conducted a review in Cardiovascular disease. Omega-3 fatty acids was evaluated. Icosapent ethyl outperforms other omega-3 fatty acids in decreasing cardiovascular disease risk and demonstrates benefits on coronary plaque progression and stabilization.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: